Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Rockwell Medical Inc(RMTI)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for RMTI
10/23/2026: RMTI (1-star) is currently NOT-A-BUY. Pass it for now.
Rockwell Medical is a specialized player in the hemodialysis supply market, focusing primarily on manufacturing and distributing liquid and powder concentrates. Its main strength lies in its established infrastructure and niche expertise, which supports recurring revenue streams. The company's primary growth story centers on operational efficiency and expanding its reach among independent dialysis clinics. However, it faces significant risks from pricing pressure in a market dominated by large, integrated competitors and high sensitivity to healthcare reimbursement policies. This stock may suit investors seeking a specialized healthcare turnaround play, though they should monitor quarterly progress on profitability and customer retention closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company is in a turnaround/scaling phase that may offer growth if execution remains strong. |
| Momentum investor | Weak fit | Momentum investors generally require sustained price appreciation trends which are not currently established. |
| Value investor | Mixed fit | Valuation may be attractive to those seeking turnaround plays, but profitability remains inconsistent. |
| Dividend investor | Weak fit | The company does not pay a dividend, making it unsuitable for income-focused investors. |
| Low-risk investor | Weak fit | Small-cap healthcare stocks inherently carry significant operational and market volatility risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-cap stocks in this sector often experience significant price swings based on news cycles. |
| Valuation risk | Medium | The stock's valuation is highly dependent on achieving and sustaining profitability targets. |
| Competition risk (Consolidated Dialysis Market) | High | The market is dominated by large players with their own supply capabilities. |
| Business quality | Medium | The business model is reliable but currently lacks the scale of dominant industry incumbents. |
| Dividend income | Low / none | Investors should not expect any income generation from this equity. |
| Execution risk | High | Success relies heavily on meeting operational efficiency targets and customer acquisition goals. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -52.16% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 27.97M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 25.1K shares | Beta 1.63 | 52 Weeks Range 4.88 - 12.90 | Updated Date 10/24/2026 |
52 Weeks Range 4.88 - 12.90 | Updated Date 10/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.34 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Dialysis Concentrates | Sale of liquid and powder acid/bicarbonate concentrates. | This is the primary source of revenue, involving high-volume, recurring sales to clinics. |
| Ancillary Supplies | Dialysis kits, medical supplies, and equipment sales. | Supplemental revenue stream derived from servicing existing dialysis clinic customers. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 24.57 | Enterprise Value 24.77M | Price to Sales(TTM) 0.4 |
Enterprise Value 24.77M | Price to Sales(TTM) 0.4 | ||
Enterprise Value to Revenue 0.36 | Enterprise Value to EBITDA 30.21 | Shares Outstanding 4.03M | Shares Floating 3.59M |
Shares Outstanding 4.03M | Shares Floating 3.59M | ||
Percent Insiders 14.78 | Percent Institutions 8.49 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.